NAMS compared with PHAT: revenue, margins and what each company keeps, and the suppliers and customers both name

NAMSNewAmsterdam Pharma Co N.V.

Mkt capRevenueRevenue

PHATPhathom Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

NAMSNewAmsterdam Pharma Co N.V.

PHATPhathom Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only NAMS 0

None

Shared 0

No disclosed counterparties: NAMS.

Only PHAT 2

—Takeda Pharmaceuticalunlistedsupplier

—Sandozunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

NAMSNewAmsterdam Pharma Co N.V.

18.90▲+0.05%· post 18.80

Mkt cap$2.3BRevenue$19MQ3 FY26Revenue$23MFY25

PHATPhathom Pharmaceuticals, Inc.

5.23▲+2.87%· post 5.23

ClosedNov 6 '26

Mkt cap$413.0MRevenue$85MQ3 FY26Revenue$175MFY25

Compare

ClosedNov 6 '26

NAMSNewAmsterdam Pharma Co N.V.

PHATPhathom Pharmaceuticals, Inc.

18.90▲+0.05%post 18.80

Price

5.23▲+2.87%post 5.23

$2.3B

Mkt cap

$413.0M

Q3 FY26$19M

Revenue

$85MQ3 FY26

FY25$23M

Revenue

$175MFY25

NAMS18.90▲+0.05%vsPHAT5.23▲+2.87%ClosedNov 6 '26